Management of infection prophylaxis in Dutch patients with myelodysplastic syndromes, a web-based case vignette questionnaire: The MINDSET study.

Autor: Rozema J; Unit of Pharmacotherapy, Epidemiology and Economics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.; Department of Clinical Pharmacy & Pharmacology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands., van Roon E; Unit of Pharmacotherapy, Epidemiology and Economics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands.; Department of Clinical Pharmacy & Pharmacology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands., Vogelzang L; Unit of Pharmacotherapy, Epidemiology and Economics, Department of Pharmacy, University of Groningen, Groningen, The Netherlands., Kibbelaar R; Pathology Friesland, Leeuwarden, The Netherlands., Veeger N; MCL Academy, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.; Department of Epidemiology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands., van de Loosdrecht A; Department of Haematology, Amsterdam University Medical Centre, Amsterdam, The Netherlands., Hoogendoorn M; Department of Internal Medicine, Medical Centre Leeuwarden, Leeuwarden, The Netherlands.
Jazyk: angličtina
Zdroj: European journal of haematology [Eur J Haematol] 2022 Oct; Vol. 109 (4), pp. 381-387. Date of Electronic Publication: 2022 Jul 06.
DOI: 10.1111/ejh.13820
Abstrakt: Objectives: Infections are a major cause of morbidity and mortality in patients with myelodysplastic syndromes (MDS). The objective of the MINDSET study was to evaluate haematologists' management of infection prevention in MDS patients using a case vignette study and to assess the availability of guidelines.
Methods: We conducted a web-based, nationwide survey amongst haematologists in the Netherlands between September and December 2021. The survey included a set of case vignettes. In addition, the availability of protocols was evaluated.
Results: Sixty responses were obtained (23.6%). These responses were well distributed across hospital types as well as level of experience. No protocols regarding infection prophylaxis specifically for MDS patients were received. In the case vignette of a 75-year-old MDS patient, respondents would primarily prescribe infection prophylaxis in case of recurrent infections (96.7%) and neutropenia (75.0% for absolute neutrophil count [ANC] < 0.2 × 10 9 /L and 53.3% for ANC < 0.5 × 10 9 /L), especially in combination with hypomethylating agents (80.0%), lenalidomide (66.7%) or chemotherapy (51.7%). Respondents would predominantly choose antibacterial agents (85.0%), followed by antifungal agents (71.7%).
Conclusions: This study showed diverse reasons and considerations of haematologists regarding whether to prescribe infection prophylaxis in MDS patients. Given the seriousness of infections in MDS patients, patient-tailored recommendations might be valuable in clinical decision-making.
(© 2022 The Authors. European Journal of Haematology published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje